Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High – Still a Buy?

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price hit a new 52-week high on Wednesday . The company traded as high as $230.52 and last traded at $231.7270, with a volume of 110118 shares traded. The stock had previously closed at $226.79.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their target price for the company from $167.00 to $219.00 in a report on Friday, May 29th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday. Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Finally, Morgan Stanley upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $185.00 to $220.00 in a research report on Wednesday, June 17th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Charles River Laboratories International Stock Performance

The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a market cap of $11.35 billion, a P/E ratio of -62.66, a P/E/G ratio of 2.58 and a beta of 1.46. The company’s 50 day moving average is $178.79 and its 200 day moving average is $183.83.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in CRL. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $43,000. Activest Wealth Management increased its position in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the period. Finally, Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at $46,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.